PD-1 Monoclonal Antibody

PD-1 monoclonal antibodies are a class of immune checkpoint inhibitors designed to target the programmed cell death protein 1 (PD-1) receptor on T cells. By binding to PD-1, these antibodies block its interaction with its ligands, PD-L1 and PD-L2, which are often overexpressed on tumor cells to evade immune detection. This blockade prevents inhibitory signaling in T cells, thereby restoring and enhancing the body's anti-tumor immune response. PD-1 monoclonal antibodies, such as pembrolizumab, nivolumab, and sintilimab, are widely used in the treatment of various malignancies, including melanoma, non-small cell lung cancer, renal cell carcinoma, and colorectal cancer, often in combination with chemotherapy, radiotherapy, or other targeted agents.

Other names

anti-PD-1 antibodyanti-PD1 antibodyanti-PD 1 antibodyanti-PD-1 monoclonal antibodyanti-PD1 monoclonal antibodyanti-PD 1 monoclonal antibodyPD-1 antibodyPD1 antibodyPD 1 antibodyPD-1 inhibitorPD1 inhibitorPD 1 inhibitor